{"id":"ts-152","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital yeast infections"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"TS-152 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, which reduces glucose reabsorption and increases glucose excretion in the urine.","oneSentence":"TS-152 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:00.036Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT04077567","phase":"PHASE3","title":"An Extension Study of TS-152 in Subjects with Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Taisho Pharmaceutical Co., Ltd.","startDate":"2019-10-01","conditions":"Rheumatoid Arthritis","enrollment":401}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ozoralizumab"],"phase":"phase_3","status":"active","brandName":"TS-152","genericName":"TS-152","companyName":"Taisho Pharmaceutical Co., Ltd.","companyId":"taisho-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TS-152 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}